Saroglitazar (a PPARα/γ dual agonist) is an anti-metabolic syndrome drug developed locally in India by the company named Zydus Cadila in 2001, which can improve insulin sensitivity, lipid, and glycemic parameters (Gowda et al., 2022). This evidence concerns the gene PPARA and metabolic syndrome.